Teva Pharmaceutical Industries, based in Israel, is the leading generic drug manufacturer in the world... Show more
TEVJF saw its Momentum Indicator move above the 0 level on August 22, 2025. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 62 similar instances where the indicator turned positive. In of the 62 cases, the stock moved higher in the following days. The odds of a move higher are at .
The Moving Average Convergence Divergence (MACD) for TEVJF just turned positive on August 28, 2025. Looking at past instances where TEVJF's MACD turned positive, the stock continued to rise in of 34 cases over the following month. The odds of a continued upward trend are .
The 50-day moving average for TEVJF moved below the 200-day moving average on August 29, 2025. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
The Aroon Indicator for TEVJF entered a downward trend on September 12, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 91, placing this stock slightly better than average.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.406) is normal, around the industry mean (17.169). P/E Ratio (0.000) is within average values for comparable stocks, (74.138). Projected Growth (PEG Ratio) (0.829) is also within normal values, averaging (1.888). TEVJF has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.030). P/S Ratio (0.987) is also within normal values, averaging (46.994).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. TEVJF’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry PharmaceuticalsGeneric